Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) Director Paolo Fundaro sold 7,246 shares of the company’s stock on the open market in a transaction dated Friday, February 14th. The shares were sold at an average price of $375.26, for a total value of $2,719,133.96. Following the sale, the director now directly owns 1,655 shares of the company’s stock, valued at approximately $621,055. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on ICPT. Analysts at Wedbush raised their price target on shares of Intercept Pharmaceuticals from $449.00 to $493.00 in a research note on Monday. Finally, analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 13th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $490.83.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 5.47% on Friday, hitting $346.51. The stock had a trading volume of 548,426 shares. Intercept Pharmaceuticals has a 52-week low of $30.38 and a 52-week high of $497.00. The stock has a 50-day moving average of $260.8 and a 200-day moving average of $104.. The company’s market cap is $6.700 billion.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.